Seventeen percent of respondents who don’t use online portals said they haven’t adopted them due to security concerns, according to a survey from LexisNexis Risk Solutions.
Data security concerns hamper patient portal uptake: survey Read More »
Hospitalist Medicine Physicians, Sound Physicians Emergency Medicine and billing provider HaloMd allegedly filed thousands of ineligible disputes into the arbitration process, costing the insurer millions of dollars.
Elevance sues Georgia providers for allegedly gaming No Surprises arbitration Read More »
Sen. Patty Murray, D-Wash., and Rep. Rosa DeLauro, D-Conn. sent a letter to the White House budget chief alleging that federal agencies, including the HHS, aren’t adequately disclosing their spending plans.
Democrat appropriators decry lack of spending transparency at HHS Read More »
While an adverse event reported in Intellia’s gene therapy trial was a “non-concern” for analysts, it follows a handful of patient deaths in other trials for the modality and sent the company’s stock tumbling in pre-market trading.
Analysts Brush Off Intellia’s Adverse Event but Gene Therapy Safety Concerns Continue Read More »
U.S. Attorney General Pam Bondi has indicated she wants to help challenge shield laws that protect clinicians offering abortion care, but the administration has sent mixed messages.
Abortion providers could face more prosecution under Trump, experts say Read More »
After a three-year IPO drought, the industry is questioning whether the window for medtech public offerings is open following a small burst of activity.
The medtech IPO window is finally open. Or is it? Read More »
Looking for a biopharma job in New York? Check out the BioSpace list of seven companies hiring life sciences professionals like you.
In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, constitutes a national security threat to the U.S.
Novo Opposes Pharma Tariffs, Urges Crackdown on Illicit Chinese Semaglutide Read More »
iTeos expects to absorb nearly $25 million in one-time costs for severance and termination payments. The biotech had 173 full-time employees at the end of 2024.
Patritumab deruxtecan was unable to significantly improve overall survival in patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations.
Merck, Daiichi Sankyo Pull NSCLC Filing for ADC, Citing Underwhelming Survival Findings Read More »
